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S U M M A R Y
Background: Neurocysticercosis is an infection of the central nervous system by the larval stage of Taenia
solium. It is a major cause of epileptic seizures in low- and middle-income countries. Corticosteroids are
frequently used to reduce inﬂammation and perilesional edema. We aimed to evaluate their efﬁcacy for
reducing the rate of seizures and lesion persistence in imaging studies.
Methods: We searched randomized controlled trials in Medline, Central, EMBASE, LILACS, and the gray
literature without language restrictions. We assessed eligibility, extracted data, and assessed the risk of
bias in the included studies. The main outcomes included seizure recurrence and lesion persistence on
imaging studies at 6–12 months of follow-up. Risk ratios (RR) were used for evaluating the main
outcomes.
Results: Thirteen studies involving 1373 participants were included. The quality of the evidence was
deemed low to very low. Corticosteroids alone versus placebo/no drug (ﬁve trials) reduced the rate of
seizure recurrence at 6–12 months (RR 0.46, 95% conﬁdence interval (CI) 0.27–0.77; 426 participants)
and the persistence of lesions in imaging studies (RR 0.63, 95% CI 0.43–0.92; 417 participants). No
differences were noted in other comparisons, including the use of corticosteroids and albendazole
combined. Corticosteroids plus albendazole increased the risk of abdominal pain, rash, and headaches
(odds ratio 8.73, 95% CI 2.09–36.5; 116 participants, one trial).
Conclusions: Although the evidence suggest corticosteroids can reduce the rate of seizure recurrence and
speed up resolution of lesions at 6–12 months of follow-up, there remains uncertainty on the effect
estimate due to a high risk of methodological and publication bias. More adequately performed
randomized trials that evaluate the use of anthelmintics, corticosteroids, and both combined against
placebo are needed.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Cerebral cysticercosis, or neurocysticercosis, is a clinical
manifestation of infestation with the cestode Taenia solium in its
larval state.1,2 It is considered the most common helminthic
infection of the central nervous system3 and a main cause of
acquired epilepsy worldwide, especially in low- and middle-
income countries of Latin America, southern Africa, and Asia,
where it is considered endemic.3
Human beings are infected by becoming an intermediate host
secondary to ingesting contaminated food containing the eggs of T.
solium. The parasite in its larval state can then reach the brain* Corresponding author. Tel.: +52 81 8888 2223; fax: +52 81 8888 2052.
E-mail addresses: carlos.cuello@itesm.mx, carlos.cuello@gmail.com
(C.A. Cuello-Garcı´a).
1201-9712/$36.00 – see front matter  2013 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2012.12.010tissue provoking a state of inﬂammation and the full clinical
picture of neurocysticercosis, including seizures, pyramidal signs,
sensory-neural and language deﬁcits, stroke, hydrocephaly, and
intracranial hypertension, among others.3,4
Three mechanisms are regarded responsible for the initial
clinical presentation:5,6 (1) mass effect, (2) direct obstruction, and
(3) perilesional inﬂammation/edema. In most patients, the
immune system eventually eliminates the parasite and provokes
a granulomatous reaction with posterior calciﬁcation and a
complete resolution in 3–24 months.4
Current therapies include anti-cyst therapies (anthelmintics
and corticosteroids) aimed at eliminating the viable cyst and
reducing perilesional brain inﬂammation, and symptomatic
therapy (i.e., anti-epileptic drugs). Commonly used anthelmintics
were recently evaluated in a Cochrane systematic review7 with
equivocal, mixed, and difﬁcult to interpret results.ses. Published by Elsevier Ltd. All rights reserved.
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known to inhibit the proliferation of the inﬂammatory
response.8,9 Their use in patients with neurocysticercosis
followed clinical observations of side effects associated with
the initiation of anthelmintic therapies.10 As inﬂammation is
deemed responsible for the majority of the clinical manifesta-
tions of the disease, it is not surprising that they are of common
use in clinical practice, and there have been several randomized
trials assessing their effectiveness with inconsistent results.4
Despite this, a systematic evaluation of the current evidence has
not been performed.
We aimed to evaluate and synthesize the evidence on the use of
corticosteroids for the treatment of children and adults with
neurocysticercosis for the resolution of seizure recurrences and
lesion disappearance on computed tomography (CT) or magnetic
resonance imaging (MRI).
2. Methods
2.1. Search strategy and selection criteria
A search strategy was constructed (Supplementary Material,
supplement 1) using the Cochrane highly sensitive search ﬁlter for
randomized controlled trials. The following databases were
scrutinized: The Cochrane Central Register of Controlled Trials
(CENTRAL), published in The Cochrane Library (The Cochrane
Library 2011, Issue 4); MEDLINE (1966 to February, week two,
2012); EMBASE (Scopus; 1947 to week two, February 2012);
LILACS (1980 to February 2012), the meta-Register of Controlled
Trials, and the World Health Organization (WHO) portal for clinical
trials. There were no restrictions on publication language.
Abstracts from congresses of infectious and neurologic disease
societies were sought. Clinical researchers, local experts and
organizations were contacted when necessary and references were
crosschecked.
We included randomized and quasi-randomized controlled
trials that evaluated both children and adults with the diagnosis of
neurocysticercosis by clinical and imaging conﬁrmation. Any type
of corticosteroid given by enteral or parenteral route was
considered as an intervention arm.
Comparisons to evaluate were: (1) corticosteroid versus
placebo/no drug; (2) corticosteroid plus albendazole versus
placebo/no drug; (3) corticosteroid versus albendazole; (4)
corticosteroid plus albendazole versus albendazole; (5) cortico-
steroid plus albendazole versus corticosteroid.
Our primary outcomes included the rate of seizure recurrence,
deﬁned as one or more convulsions after the initial episode and
within 12 months of the ﬁrst seizure, and the rate of lesion
persistence on the imaging studies, by MRI or CT scan. Radiologic
resolution was deﬁned when the lesion completely disappeared,
with none or minimal residual scar, calciﬁcation, or perilesional
edema.
Secondary outcomes included adverse events related to the
corticosteroid therapy, i.e., headaches, abdominal pain, rash, and
other infections. Although death was considered unlikely to
happen, any such event was sought and analyzed.
2.2. Data extraction
Two authors (CC and YR) independently assessed the eligibility
of studies, and based on the inclusion criteria, extracted data and
assessed the risk of bias of the included studies on a pre-piloted
data extraction form. Discrepancies were resolved with the third
and fourth authors (GP and JV). Data to extract included the setting,
patient characteristics, year of study, deﬁnitions, and results based
on the primary and secondary outcomes.2.3. Quality assessment
Two authors (CC and YR) independently evaluated the risk of
bias for each included study. Any discrepancies were settled
with the third and fourth authors (GP and JV) by informal
consensus.
The Cochrane Collaboration’s tool11 for assessing risk of bias
was used, and it includes an assessment of: (1) an adequate
sequence generation, (2) allocation concealment, (3) blinding
(masking) of participants, personnel, and outcome assessors, (4) if
incomplete outcome data was possible, (5) selective outcome
reporting, and (6) if other sources of bias were considered.
We determined the risk of bias for each component using ‘yes’,
‘no’, or ‘unclear’, indicating a low, high, or unclear/unknown risk of
bias, respectively.
2.4. Statistical analysis
Review Manager 5.1 software was used for the data synthesis
and analysis. Combined risk ratios (RR) for dichotomous outcomes
were used with the Mantel–Haenszel method and a random effects
model approach. We expected a low rate of adverse events and
decided to use the Peto odds ratio (OR) for the adverse event
outcome.
Considering unit of analysis issues in trials with more than two
intervention arms of study, the number of participants was evenly
divided and analyzed as individual pair-wise comparisons to
ensure that participants in the placebo group were not counted
more than once. Whenever possible and if necessary, data on all
participants were extracted from studies that reported sufﬁcient
information for an intention-to-treat analysis. We tried to contact
authors of individual studies if details of trial design or descriptive
statistics for outcomes were not present in the study. If the authors
did not respond within 3–6 weeks, we conducted the review based
only on the available information.
We evaluated heterogeneity using forest plots to detect
overlapping conﬁdence intervals, and applied the Chi-square test,
with a p-value of 0.10 used to indicate statistical signiﬁcance. We
also implemented the I2 statistic, with a value of 50% used to
denote moderate levels of heterogeneity.
Publication bias was visually assessed with funnel plots on
different comparisons looking for asymmetry. We also tried to
contact experts and authors of identiﬁed studies and ask whether
they had other publications or were aware of any other
unpublished studies. Public trial registries were also searched
for ongoing or incomplete studies.
Overall evidence was assessed using the GRADE approach, and
summary of ﬁndings tables were constructed using GRADEpro
software.12,13
Sensitivity analyses were devised based on: (1) the quality of
individual trials (blinding of outcome assessors, blinding of
participants, and levels of attrition bias), (2) age of participants
(children vs. adults), and (3) the type of lesion in the imaging study
as ‘viable’, ‘non-viable’, or mixed.7
3. Results
3.1. Results of the search
The preliminary searches identiﬁed 63 potential citations. We
read the titles and abstracts of these studies. Thirteen articles with
1373 participants were determined to be eligible (Figure 1). All of
them were included in the ﬁnal quantitative and qualitative
analysis and are described in Table 1. The excluded studies and
reasons for their exclusion are given in the Supplementary
Material (supplement 2).
# of records after duplicates 
removed (63)
# of records 
screened (63)
# of studies included 
in quantitative 
synthesis (meta -
analysis) (13)
# of studies in clud ed 
in qualit ative 
synthesis ( 13)
# of full -text 
articles assessed for 
eligibility (57)
# of records 
identified through 
database searching 
(61)
# of additional 
records identified 
through other 
sources (2)
# of records excluded (6)
Evaluated vaccines (6)
# of full-text articles 
excluded (44)
Not relevant to our 
study (4)
Other systematic 
reviews (5)
Narrative reviews (22)
Other treatments (8)
Case series (2)
Case reports (2)
Study in animals (1)
Figure 1. Study ﬂowchart.
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Regarding allocation (selection) bias, only ﬁve studies10,14–17
had a good description of how the random sequence list was
generated. Of these, only one15 did not describe a proper allocation
concealment process (i.e., sealed opaque envelopes or a statistician
not involved in the process of allocation).
Four trials10,14,15,17 adequately blinded personnel and partici-
pants of the study by using and describing placebos, as well as the
blinding of the outcome assessors.Attrition bias was deemed unlikely among most of the studies.
Only in three studies17–19 were dropouts considered sufﬁcient to
be classiﬁed as unclear risk, and in two trials14,16 there were
concerns about dropouts and their adequate analyses, hence a high
risk of bias was considered and sensitivity analyses were
performed as described below.
All studies had a low risk of reporting (selective reporting)
bias.
The risk of bias estimations are visually summarized in a risk of
bias graphic in the Supplementary Material (supplement 3).
Table 1
Studies included in the quantitative analysis
Study Methods Participants Interventions Outcomes Notes
Carpio et al.18
1995
Quasi-RCT
Duration: 47 months;
from July 1986 to
June1990
n = 175 adults with
evidence of active
neurocysticercosis by
CT scan
Exclusion criteria:
severe medical illness,
intraventricular cysts,
hydrocephalus, CT
evidence of
transitional forms
(degenerative cysts)
1. Albendazole (15 mg/kg/
day PO for 8 days) plus
prednisolone
2. Praziquantel (50 mg/kg/
day PO for 15 days) plus
prednisolone
3. Prednisolone alone
All doses of prednisolone
at 1 mg/kg day PO for 15
days
1. Cyst free at 3–6 months
on CT
2. Number of cysts
3. Rate of seizure
recurrence at 3–6 months
Location: Cuenca, Ecuador
Setting: hospital and
ambulatory setting
Source of funding:
university council and
Fogarty International
Center
Gogia et al.15
2003
RCT
Duration: 4 months; from
March 2000 to July 2000
n = 72 children with
new-onset seizure and
CT scan showing lesion
Exclusion criteria:
calciﬁed or in
regression lesions;
known diseases or
patients who received
AED or anthelmintics
1. Albendazole (15 mg/kg/
day for 28 days) plus
prednisolone (2 mg/kg/
day for 3 days)
2. Placebo plus
prednisolone as above
All patients received AED
1. Rate of seizure
recurrence at 6 months
2. Lesion persistence at 6
months on the CT
Location: New Delhi, India
Setting: hospital and
ambulatory settings
Source of funding: none
declared
Kalra et al.16
2003
RCT
Duration: not described
n = 123 children with
new onset seizures; 1
or 2 ring-enhancing
lesions <20 mm on CT
Exclusion criteria:
tuberculosis,
intraocular cysts or
with multiple lesions
(>2), disk or calciﬁed
lesions,
intraventricular cysts,
or hydrocephalus
1. Dexamethasone (0.15
mg/kg/day for 5 days) plus
albendazole (15 mg/kg/
day for 28 days)
2. Control (nothing)
AED used in both groups
1. Persistence of the lesion
at 3 months on CT scan
2. Rate of seizure
recurrence at 3–6 months
Location: New Delhi, India
Setting: hospital and
ambulatory setting
Source of funding: not
declared
Mall et al.22
2003
RCT
Duration: 11 months;
from October 2001 to
September 2002
n = 97 children and
adults with new onset
seizures and
enhancing lesion on CT
Exclusion criteria:
neurologic deﬁcit,
increased ICP, systemic
disease
1. Prednisolone (1 mg/kg/
day; PO QD for 10 days)
2. Control group
AED used in both groups
1. Lesion on CT scan
disappeared at 6 months
2. Rate of seizure
recurrence at 6 months
Location: Lucknow, India
Setting: hospital and
ambulatory
Source of funding: none
declared
Garcia et al.10
2004
RCT
Duration: 26 months;
from January 1997 to
March 1999
n = 120 adults with
cysts on CT scan,
serologic conﬁrmation,
spontaneous seizures
within 6 months
Exclusion criteria:
AHD, >20 cysts on CT,
other diseases,
increased ICP,
pregnancy
1. Albendazole (400 mg
bid for 10 days) plus
dexamethasone (2 mg tid
for 10 days)
2. Placebos (two)
1. Rate of seizure
recurrence at 2–30
months
2. Lesion persistence at 6
months on MRI
Location: Lima, Peru
Setting: hospital and
ambulatory
Source of funding: FDA,
National Institute of
Allergy, and SmithKline
Beecham
Singhi et al.25
2004
RCT
Duration: not described
n = 110 children with
new onset seizures and
CT scan with lesion
Exclusion criteria:
neurologic deﬁcits,
systemic disease
1. Prednisolone (2 mg/kg/
day for 3 weeks)
2. Albendazole (15 mg/kg/
day for 4 weeks)
3. Prednisolone plus
albendazole (as above)
All patients received AED
1. Rate of seizure
recurrence at 18 months
2. Lesion persistence at 6
months on CT scan
Location: Chandigarh,
India
Setting: hospital and
ambulatory
Source of funding: none
declared
Prakash et al.23
2006
RCT
Duration: 11 months;
from February 2003 to
January 2004
n = 52 children and
adults with new-onset
seizure and CT scan
enhancing lesion of
less than 20 mm
Exclusion criteria:
raised ICP, focal
neurological deﬁcits,
peptic ulcer disease,
previous AHD
1. Methylprednisolone
(1.0 g/1.72 m2/day IV for 5
days)
2. Control (no therapy)
All patients received AED
1. Rate of seizure
recurrence at 9 months
2. Lesion persistence at 2
months on the CT scan
Location: Lucknow, India
Setting: hospital and
ambulatory
Source of funding: not
described
Garg et al.20
2006
RCT
Duration: 12 months;
from February 2004 to
February 2005
n = 60 children and
adults with new-onset
seizure and enhancing
lesion <20 mm
Exclusion criteria:
raised ICP,
neurological deﬁcits,
prior AHD, history of
peptic ulcer disease
1. Prednisolone (1 mg/kg/
day for 10 days)
2. Placebo
All patients received AED
1. Rate of seizure
recurrence at 6 months
2. Lesion persistence at 6
months on the CT
Location: Lucknow, India
Setting: hospital and
ambulatory settings
Source of funding: none
declared
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Kishore and Misra21
2007
RCT
Duration: not described
n = 100 children and
adults with new onset
seizure and enhanced
lesion on CT
Exclusion criteria:
raised ICP, progressive
neurological deﬁcit,
and systemic disease
1. Prednisolone (1 mg/kg/
day for 10 days)
2. Placebo
All patients received AED
1. Rate of seizure
recurrence at 3 months
2. Persistence of the lesion
on CT at 3 months
Location: Varanasi, India
Setting: hospital and
ambulatory
Source of funding: not
described
Das et al.24
2007
RCT
Duration: 8 years; from
January 1997 to January
2005
n = 300 adults with CT
and MRI with at least 2
lesions, at least 1 in the
vesicular stage;
antibodies against
cysticercosis
Exclusion criteria:
primary seizure, pre-
existing focal
neurological deﬁcit, or
any metabolic or
hereditary disease
1. Albendazole (15 mg/kg/
day PO for 14 days) plus
dexamethasone (2 mg tid
PO for 14 days)
2. Placebo
All patients received AED
1. Rate of seizure
recurrence at 6 months
2. Lesion persistence at 6
months on the MRI scan
Location: Burdwan, India
Setting: hospital and
ambulatory
Source of funding:
Principal and
Superintendent of
Burdwan Medical College
Sharma et al.19
2007
RCT
Duration: 25 months;
from December 2002 to
January 2004
n = 90 children and
adults with new-onset
seizure; CT scan lesion
Exclusion criteria:
previous AHD, other
serious diseases
1. Albendazole (15 mg/kg/
day for 4 days) plus
prednisolone (1 mg/kg/
day for 14 days)
2. Prednisolone alone as
above
All patients were given
AED
1. Rate of seizure
recurrence at 6 months
2. Lesion persistence at 6
months on the CT scan
Location: Lucknow, India
Setting: hospital and
ambulatory
Source of funding: none
declared
Carpio et al.14
2008
RCT
Duration: 24 months;
from February 2001 to
February 2003
n = 178 children and
adults with new onset
of symptoms and
active and/or
transitional cysts on CT
or MRI
Exclusion criteria: only
calciﬁcations on CT,
pregnancy,
papilledema, ocular
cysticercosis, any
progressive or life-
threatening disorder,
previous AHD or
steroids
1. Albendazole (15 mg/kg/
day for 8 days) plus
prednisone (1.5 mg/kg/
day for 8 days)
2. Placebo plus prednisone
as above
All patients were given
AED
1. Lesion persistence at 12
months on CT scan
2. Rate of seizure
recurrence at 12 months
Location: Ecuador
Setting: hospital and
ambulatory
Source of funding: NINDS
grant #R01-NS39403,
Glaxo/SKB and Acromax
Co. supplied active drug
and placebo
Trial registration number:
NCT00283699
Singla et al.17
2011
RCT
Duration: 17 months;
from July 2007 to
December 2008
n = 148 adults with
new-onset seizures,
MRI or CT with viable
lesion
Exclusion criteria:
calciﬁc lesions on
imaging; CNS,
pulmonary or systemic
disease; positive HIV;
pregnant women;
prior AHD or
corticosteroids
1. Prednisolone (>40 kg,
60 mg/day; <40 kg, 40
mg/day for 2 weeks)
2. Placebo
All patients received AED
1. Rate of seizure
recurrence at 9 months
2. Lesion persistence at 6
months on the MRI
Location: Chandigarh,
India
Setting: hospital and
ambulatory
Source of funding: none
declared
AED, anti-epileptic drug; AHD, anthelmintic drug; bid, twice daily; CNS, central nervous system; CT, computed tomography; FDA, U.S. Food and Drug Administration; HIV,
human immunodeﬁciency virus; ICP, intracranial pressure; IV, intravenous; MRI, magnetic resonance imaging; NINDS, National Institute of Neurological Disorders and
Stroke; PO, oral route; QD, once daily; RCT, randomized controlled trial; tid, three times daily; SKB, SmithKline Beecham.
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Material, supplement 4), publication bias was considered highly
possible.
3.3. Effects of interventions
3.3.1. Corticosteroids versus no drug or placebo
Five studies comparing corticosteroid alone to no drug/placebo
were included.17,20–23 The rate of seizure recurrence at 6–12
months of follow-up was reduced in the corticosteroid group (RR
0.46, 95% CI 0.27–0.77; 426 participants, ﬁve trials).
Also, corticosteroids reduced the rate of lesion persistence on
MRI or CT scan at 6–12 months of follow-up (RR 0.63, 95% CI 0.43–
0.92; 417 participants, ﬁve trials); see Figure 2.3.3.2. Corticosteroids plus albendazole versus no drug or placebo
Three studies10,16,24 evaluated this combination compared to
no drug/placebo. There were no statistically signiﬁcant effects of
this combination for reducing the rate of seizure recurrence (RR
0.98, 95% CI 0.53–1.82; 504 participants, three trials) or lesion
persistence in imaging studies (RR 0.88, 95% CI 0.69–1.12; 500
participants, three trials) (Figure 3).
3.3.3. Corticosteroids versus albendazole
Only one study25 evaluated this comparison in a three-arm
clinical trial. No statistically signiﬁcant difference was detected for
reducing the rate of seizures (RR 3.5, 95% CI 0.83–14.7; 38
participants) or the rate of lesion persistence (RR 1.00, 95% CI 0.35–
2.90; 38 participants).
Figure 2. Forest plots of comparison corticosteroids vs. placebo/no drug.
Figure 3. Forest plots of comparison corticosteroids plus albendazole vs. placebo/no drug.
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Figure 4. Forest plots of comparison corticosteroid plus albendazole vs. corticosteroid.
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One three-arm trial25 evaluated this comparison. No statisti-
cally signiﬁcant differences were observed for seizure recurrence
(RR 1.42, 95% CI 0.27–7.46; 35 participants) or for the rate of lesion
persistence in imaging studies (RR 0.94, 95% CI 0.28–3.19; 35
participants).
3.3.5. Corticosteroids plus albendazole versus corticosteroids
Five studies evaluated this comparison.14,15,18,19,25 The com-
bined effect did not have an effect on seizure recurrence (RR 1.03,
95% CI 0.62–1.71; 370 participants) or on lesion persistence in
imaging studies (RR 0.88, 95% CI 0.75–1.05; 365 participants)
(Figure 4).
3.3.6. Sensitivity analyses
We ﬁrst performed a sensitivity analysis based on the risk of
bias of individual studies.
On the comparison of corticosteroids versus placebo/no drug
(with ﬁve trials), only the study by Singla et al.17 had a low risk of
bias, with a result of no difference between arms of the study for
both the outcome of seizure recurrence (RR 0.86, 95% CI 0.49–1.51)
and lesion persistence in imaging studies (RR 0.89 95% CI 0.64–
1.22); the ﬁnal result with only the four high risk of bias studies
remained signiﬁcant.
On the comparison of corticosteroids plus albendazole versus
placebo/no drug, the exclusion of high risk of bias studies left
the analysis with only one good quality study,10 for which
results showed no effect on the rate of seizure recurrence (RR
1.04, 95% CI 0.75–1.44), but showed signiﬁcant results for the
rate of lesion persistence in imaging studies (RR 0.73, 95% CI
0.57–0.92).
On the comparison of corticosteroids plus albendazole versus
corticosteroids alone, two studies14,15 out of ﬁve had a low risk of
bias. Excluding high risk of bias studies did not have an effect onthe initial result of non-signiﬁcance in both outcomes.We also
performed a sensitivity analysis based on age, i.e., trials studying
only children,15,16,25 only adults,10,17,18,24 and those where
separating children from adults was not feasible.14,19–23
In the comparison of corticosteroids versus placebo/no drug,
out of ﬁve studies, only one17 included adults exclusively.
Excluding this trial made no difference to the ﬁnal result in any
outcome.
Within three studies10,16,24 that compared corticosteroids plus
albendazole versus placebo/no drug, one study16 included pediat-
ric participants only; the effect of removing it from the analysis did
not provoke a change in the ﬁnal result of no signiﬁcance, although
this pediatric trial considered alone favored the intervention for
reducing the rate of seizure recurrence.
On the comparison of corticosteroids plus albendazole versus
corticosteroids alone, out of ﬁve trials, only two15,25 included
children exclusively. Removing them elicited no changes.
Our last sensitivity analysis was based on viable, non-viable, or
mixed lesions. Out of the initial 13, only two trials10,18 included
exclusively patients with viable lesions; two other trials14,24
included both viable and non-viable lesions and the other nine
studies included only non-viable lesions. No change in the ﬁnal
effect was observed in all comparisons and in all outcomes
evaluated. Further sensitivity analyses were not feasible (i.e.,
number and/or location of the lesions) because of a lack of
information from individual studies.
3.4. Adverse events
This outcome was difﬁcult to ascertain, as there were different
deﬁnitions and probable underreporting among different trials. On
qualitative analysis, the most common reported adverse reactions
were skin rashes, erythema multiforme minor, headache, and
abdominal pain or discomfort.
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not increase adverse events (Peto OR 0.46 95% CI 0.17–1.25; 355
participants, four studies).17,20,22,23
There were no studies evaluating adverse events in the
comparisons of corticosteroids versus albendazole, or corticoste-
roids plus albendazole versus albendazole.
However, when compared to no therapy or placebo the
combination of corticosteroids plus albendazole increased the
risk of abdominal pain and abdominal discomfort (Peto OR 8.73,
95% CI 2.09–36.5; 116 participants, one trial).10 Also, this
combination increased the risk of presenting abdominal pain or
headache when compared to corticosteroids alone (Peto OR 4.90,
95% CI 1.84–13.06; 191 participants, two studies).14,18
The death rate was similar among study groups in those trials
that reported this outcome.
4. Discussion
Inﬂammation is considered responsible for the clinical manifes-
tations in patients with cerebral cysticercosis.4 Corticosteroids have
been indicated as a ﬁrst-line therapy by clinicians who justify their
use hoping to control the inﬂammatory response that occurs during
the natural disappearance of the lesions, or as a result of
anthelmintic therapy. Notwithstanding this being a common
textbook approach26 and a current recommendation in clinical
practice guidelines,27 there is no unique regimen or standard of use.
In this systematic review corticosteroids used alone reduced the
rate of seizure recurrence and the persistence of lesions in imaging
studies in a range of 6–12 months of follow-up. However, with the
exception of one study,17 all trials making this comparison were
considered as having a high risk of bias, hence the overall body of
evidence was weighted as very low quality using the GRADE
approach (Table 2). It is important to note the critical possibility of
publication bias, as it was evident from visual inspection in the
funnel plot (Supplementary Material, supplement 4).
With the current evidence analyzed, we cannot be certain
whether corticosteroids used alone or in combination with anTable 2
GRADE summary of ﬁndings table: corticosteroids versus placebo/no drug
Patient or population: patients with neurocysticercosis; settings: hospital and amb
Outcomes Illustrative comparative risksa (95% CI) Relative e
(95% CI)
Assumed risk Corresponding risk
Placebo or no drugs Corticosteroids alone
Seizure recurrence
Clinical evaluation
Follow-up: 6–12 months
31 per 100 14 per 100
(8 to 24)
RR 0.46
(0.27 to 0
Persistence of lesions on
imaging studies
CT scan or MRI
Follow-up: 6–12 months
56 per 100 35 per 100
(24 to 52)
RR 0.63
(0.43 to 0
Adverse events
Clinical evaluation
Follow-up: 1–3 months
6 per 100 3 per 100
(1 to 8)
OR 0.46
(0.17 to 1
CI, conﬁdence interval; CT, computed tomography; MRI, magnetic resonance imaging;
a The basis for the assumed risk (e.g., the median control group risk across studies) is pr
risk in the comparison group and the relative effect of the intervention (and its 95% C
b GRADE Working Group grades of evidence: high quality: further research is very un
research is likely to have an important impact on our conﬁdence in the estimate of effect
important impact on our conﬁdence in the estimate of effect and is likely to change th
c Except for the study by Singla et al.,17 random sequence generation, random alloca
assessment.
d Wide conﬁdence intervals among important clinical outcomes.
e See funnel plot asymmetry (Supplementary Material, supplement 4).
f Concerns over methodological heterogeneity.
g Different deﬁnitions of adverse events, and different events evaluated across studianthelmintic could provide more desirable than undesirable
effects.
Combining corticosteroids and albendazole is an option that
could make sense in clinical practice. However, our results did not
show an effect on reducing the rate of seizure recurrence or lesion
persistence in imaging studies. Within the three studies that
evaluated these outcomes, only one trial with a low risk of bias10
showed a beneﬁt of using this combination. The other two
presented a high risk of bias and wide conﬁdence intervals
(Table 3). Furthermore adverse events (abdominal pain or
discomfort) were more frequently reported.
We evaluated other comparisons, but none of them showed a
statistical or clinical signiﬁcance, and most of the studies included
had an increased risk of bias.
The comparisons of corticosteroids versus albendazole and
corticosteroids plus albendazole versus albendazole alone were
assessed in the three-arm study of Singhi et al.,25 showing no
difference between the study arms and wide conﬁdence intervals
to reach a conclusion.
We found ﬁve studies evaluating corticosteroids plus albenda-
zole versus corticosteroids alone, and although there was a
tendency for this combination towards reducing the rate of lesion
persistence in imaging studies, it did not reach statistical
signiﬁcance, the overall quality of the evidence was deemed low
to very low (Table 4), and adverse events (headache and abdominal
pain) were signiﬁcantly more frequent in the intervention group.
This systematic review might have some limitations. Overall
the quality of the evidence of included studies assessed with the
GRADE methodology was considered from very low to moderate.
Although all 13 studies are classiﬁed as randomized, only a few
adequately described sequence generation or allocation conceal-
ment.
Patients participating in the included studies were from low-
and middle-income countries (Ecuador, India, and Peru) and were
recruited mostly from tertiary care centers; no studies from high-
income countries were found, thus the applicability of the evidence
in these settings remains questionable.ulatory; intervention: corticosteroids alone; comparison: placebo or no drugs
ffect Number of participants
(studies)
Quality of the evidenceb
(GRADE)
Comments
.77)
426
(5 studies) Very lowc,d,e
.92)
417
(5 studies) Very lowc,d,e,f
In one study17
MRI was used to
assess the
outcome
.25)
355
(4 studies) Very lowc,d,e,f,g
Rash or abdominal
pain were
considered for
this comparison
 OR, odds ratio (Peto); RR, risk ratio.
ovided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed
I).
likely to change our conﬁdence in the estimate of effect; moderate quality: further
 and may change the estimate; low quality: further research is very likely to have an
e estimate; very low quality: we are very uncertain about the estimate.
tion concealment, and blinding not described or poorly performed; poor outcome
es.
Table 3
GRADE summary of ﬁndings table: corticosteroids plus albendazole versus placebo/no drug
Patient or population: patients with neurocysticercosis; settings: hospital and ambulatory; intervention: corticosteroids plus albendazole; comparison: placebo or no
drugs
Outcomes Illustrative comparative risksa (95%
CI)
Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidenceb
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo or no
drugs
Corticosteroids plus
albendazole
Seizure recurrence
Clinical evaluation
Follow-up: 6–12 months
280 per 1000 274 per 1000
(148 to 509)
RR 0.98
(0.53 to 1.82)
504
(3 studies) Very lowc,d
One trial16 with low risk
of bias showed
a reduction of the rate of
seizure recurrence
Persistence of lesions on
imaging studies
CT scan or MRI
Follow-up: 6–12 months
88 per 100 78 per 100
(61 to 99)
RR 0.88
(0.69 to 1.12)
500
(3 studies) Very lowc,d
Only one trial16 used
CT scan as the imaging study
Adverse events
Clinical evaluation
Follow-up: 1–3 months
5 per 100 87 per 100
(5 to 100)
OR 8.73
(2.09 to 36.5)
116
(1 study) Moderatee
Rate of abdominal pain episodes
Other events (rash, headache,
paresis, etc.) not signiﬁcantly
different between groups
CI, conﬁdence interval; CT, computed tomography; MRI, magnetic resonance imaging; OR, odds ratio (Peto); RR, risk ratio.
a The basis for the assumed risk (e.g., the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed
risk in the comparison group and the relative effect of the intervention (and its 95% CI).
b GRADE Working Group grades of evidence: high quality: further research is very unlikely to change our conﬁdence in the estimate of effect; moderate quality: further
research is likely to have an important impact on our conﬁdence in the estimate of effect and may change the estimate; low quality: further research is very likely to have an
important impact on our conﬁdence in the estimate of effect and is likely to change the estimate; very low quality: we are very uncertain about the estimate.
c One study with a poor description of the random sequence generation and allocation concealment.
d High heterogeneity.
e Only adults were evaluated (may not apply to children).
C.A. Cuello-Garcı´a et al. / International Journal of Infectious Diseases 17 (2013) e583–e592 e591Regarding age groups, only three trials included exclusively
pediatric participants. The sensitivity analyses did not demon-
strate a different effect between children and adults. Whether
corticosteroids or different combinations have a different effect on
children and adults is difﬁcult to ascertain and more studies are
necessary to elucidate this issue.
Because of a lack of information from individual studies, we
could not perform sensitivity analyses regarding the number, type,Table 4
GRADE summary of ﬁndings table: corticosteroids plus albendazole versus corticostero
Patient or population: patients with neurocysticercosis; settings: hospital/ambulato
alone
Outcomes Illustrative comparative risksa (95% CI) Relative effe
(95% CI)
Assumed risk Corresponding risk
Corticosteroids
alone
Corticosteroids plus
albendazole
Seizure recurrence
Clinical evaluation
Follow-up: 6–12 months
289 per 1000 283 per 1000
(208 to 387)
RR 0.98
(0.72 to 1.3
Persistence of lesions on
imaging studies
CT scan or MRI
Follow-up: 6–12 months
58 per 100 50 per 100
(41 to 59)
RR 0.86
(0.72 to 1.0
Adverse events
Clinical evaluation
Follow-up: 1–3 months
61 per 100 89 per 100
(75 to 95)
OR 4.9
(1.84 to 13)
CI, conﬁdence interval; CT, computed tomography; MRI, magnetic resonance imaging;
a The basis for the assumed risk (e.g., the median control group risk across studies) is pr
risk in the comparison group and the relative effect of the intervention (and its 95% C
b GRADE Working Group grades of evidence: high quality: further research is very un
research is likely to have an important impact on our conﬁdence in the estimate of effect
important impact on our conﬁdence in the estimate of effect and is likely to change th
c Only one study with a description of the random sequence generation, allocation c
d Borderline heterogeneity (49%) among studies.
e Concerns regarding different forms of evaluation of clinical outcomes and prevalen
f Wide conﬁdence intervals.and/or location of the lesions; we are aware that these could be
important prognostic factors to consider in future studies.
Even when every effort was made to retrieve all relevant trials
without restrictions, the possibility of publication bias was
deemed high on visual inspection in the funnel plot (Supplemen-
tary Material, supplement 4). This observation is of concern, as
there is a high possibility that those trials with negative results are
not being published, and their inclusion could change theids
ry; intervention: corticosteroids plus albendazole; comparison: corticosteroids
ct Number of participants
(studies)
Quality of the evidenceb
(GRADE)
Comments
4)
370
(5 studies) Very lowc,d
2)
365
(5 studies) Lowc
All trials used
CT scan as the
imaging study
191
(2 studies) Very lowc,d,e,f
Headache,
abdominal pain,
abdominal
discomfort
 OR, odds ratio (Peto); RR, risk ratio.
ovided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed
I).
likely to change our conﬁdence in the estimate of effect; moderate quality: further
 and may change the estimate; low quality: further research is very likely to have an
e estimate; very low quality: we are very uncertain about the estimate.
oncealment, and blinding.
ce of the outcome in the control (corticosteroid) group.
C.A. Cuello-Garcı´a et al. / International Journal of Infectious Diseases 17 (2013) e583–e592e592direction of our ﬁndings on several comparisons in this systematic
review.
As with any systematic review, the process of data extraction,
assessments of the risk of bias, and data entry are subjective and
might be prone to errors.
To our knowledge this is the ﬁrst systematic review addressing
the comparisons between corticosteroids versus placebo or no
drugs or a combination of therapies that include at least a
corticosteroid in one arm.
Diverse recommendations from different sources might be
confusing for the clinician. Some clinical practice guidelines and
expert consensuses state that corticosteroids could have some
beneﬁt in speciﬁc situations (e.g., periventricular cysts and large
cysts in the Sylvian ﬁssure),27 meanwhile other information
resources for clinicians still consider corticosteroids as a ﬁrst-line
therapy for all types of presentations;26 none of these recom-
mendations, however, are based on solid evidence.
A recent narrative review4 addressed the use of corticosteroids
in patients with neurocysticercosis, but there was no formal
description of the search strategy, data extraction, assessment
of risk of bias, or a formal compilation of the results in a
meta-analysis.
Regarding the use of anthelmintics, a recent Cochrane
systematic review by Abba et al.7 evaluated the use of albendazole
for patients with neurocysticercosis. They also studied the
combinations included in our review and their conclusions are
mostly in agreement with our results. Although the authors
emphasize using sub-group analyses based on viable or non-viable
lesions, in our sensitivity analysis we did not ﬁnd this dichotomi-
zation clinically different or useful. The authors concluded that
albendazole might reduce the rate of seizure recurrence and lesion
persistence and assert that the evidence is equivocal and more
studies are needed.
Future studies should include an adequate sample size, random
sequence generation, allocation concealment, and blind measure-
ment of clinical endpoints. They should address the same clinical
outcomes of seizure recurrence and lesion persistence in imaging
studies, and even add the acute effects (mass effect and seizures in
the ﬁrst hours after treatment). A factorial design might achieve
these goals and ideally the arms of the study would be: (1)
corticosteroids alone, (2) corticosteroids plus albendazole, (3)
albendazole, and (4) placebo. Stratiﬁcation of the study should be
considered regarding age and type, location, size, and number of
cysts in imaging studies.
In conclusion, due to a high risk of methodological bias as
well as publication bias we cannot be certain whether
corticosteroids alone or in combination with anthelmintics
could reduce the rate of seizure recurrence or lesion disappear-
ance in imaging studies. Although our results suggest cortico-
steroids can reduce the rate of seizure recurrence and speed up
resolution of lesions, there remains uncertainty on the effect
estimate and further research is very likely to change our
conﬁdence in these results. If clinicians decide to use corticoste-
roids as a ﬁrst-line therapy, they should consider carefully if the
possible beneﬁts outweigh the risks and consider the costs on an
individual patient basis.
Conﬂict of interest: We certify that we have no afﬁliations with
or involvement in any organization or entity with a direct ﬁnancial
interest in the subject matter of the review (e.g., employment,
consultancy, stock ownership, honoraria, and expert testimony).
Ethical approval: As a systematic review of the evidence, this
work has no need for ethical approval. However the protocol was
submitted to the Institutional Review Board for their clearance and
for the archives within the Tecnolo´gico de Monterrey School of
Medicine.Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.ijid.2012.12.010.
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